TY - JOUR
T1 - thy/liv-SCID-hu mice
T2 - A system for investigating the in vivo effects of multidrug therapy on plasma viremia and human immunodeficiency virus replication in lymphoid tissues
AU - Pettoello-Mantovani, Massimo
AU - Kollmann, Tobias R.
AU - Katopodis, Nikos F.
AU - Raker, Christina
AU - Kim, Ana
AU - Yurasov, Sergey
AU - Wiltshire, Hugh
AU - Goldstein, Harris
N1 - Funding Information:
Grant support: NIH (Al-36664, Al-27741, and CA-09173 [to M.P.M.]). Flow cytometry was performed in the Flow Cytometry Core Facility (Albert Einstein College of Medicine), and oligonucleotides were synthesized in the Oligonucleotide Synthesis Core Facility (Albert Einstein College of Medicine) supported by NIH grant CA-13330.
PY - 1998
Y1 - 1998
N2 - Modified, human immunodeficiency virus (HIV)-inoculated thy/liv-SCID-hu mice were used to evaluate the in vivo efficacy of antiretroviral drugs. Ritonavir treatment alone initially suppressed plasma viremia, but the viremia recurred with the appearance of ritonavir-resistant HIV isolates. Multidrug therapy suppressed plasma HIV RNA to undetectable levels; however, plasma viremia returned after therapy was stopped, showing that the therapy did not completely suppress HIV infection in the thymic implant. When thy/liv-SCID-hu mice were treated with a combination of zidovudine, lamivudine, and ritonavir immediately after inoculation with HIV, cocultures of the thymic implants remained negative for HIV even 1 month after therapy was discontinued, suggesting that acute treatment can prevent the establishment of HIV infection. Thus, these modified thy/liv-SCID-hu mice should prove to be a useful system for evaluating the effectiveness of different antiretroviral therapies on acute and chronic HIV infection.
AB - Modified, human immunodeficiency virus (HIV)-inoculated thy/liv-SCID-hu mice were used to evaluate the in vivo efficacy of antiretroviral drugs. Ritonavir treatment alone initially suppressed plasma viremia, but the viremia recurred with the appearance of ritonavir-resistant HIV isolates. Multidrug therapy suppressed plasma HIV RNA to undetectable levels; however, plasma viremia returned after therapy was stopped, showing that the therapy did not completely suppress HIV infection in the thymic implant. When thy/liv-SCID-hu mice were treated with a combination of zidovudine, lamivudine, and ritonavir immediately after inoculation with HIV, cocultures of the thymic implants remained negative for HIV even 1 month after therapy was discontinued, suggesting that acute treatment can prevent the establishment of HIV infection. Thus, these modified thy/liv-SCID-hu mice should prove to be a useful system for evaluating the effectiveness of different antiretroviral therapies on acute and chronic HIV infection.
UR - http://www.scopus.com/inward/record.url?scp=0031883198&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031883198&partnerID=8YFLogxK
U2 - 10.1086/514214
DO - 10.1086/514214
M3 - Article
C2 - 9466519
AN - SCOPUS:0031883198
SN - 0022-1899
VL - 177
SP - 337
EP - 346
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
IS - 2
ER -